ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

With the business potentially at an important milestone, we thought we'd take a closer look at BeiGene, Ltd.'s... BeiGene stock just hit that mark, with a jump from 69 to 84 Wednesday. Is BeiGene ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of $286.00. Kelly Shi’s rating is based on a ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

BGB-15025 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...

David Li, an analyst from Bank of America Securities, maintained the Hold rating on BeiGene (ONC – Research Report). The associated price target remains the same with $207.00. Discover ...